+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
ID07845630

Bioequivalence Study of Two Vicadrostat and Empagliflozin Tablet Formulations in Healthy Adults Using a Randomized Crossover Design

Led by Boehringer Ingelheim · Updated on 2026-10-29

36

Participants Needed

1

Research Sites

1 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the bioequivalence of two different oral formulations of vicadrostat and empagliflozin in healthy male and female adults aged 18 to 55 years. This Phase 1, randomized, open-label, single-dose, two-period crossover trial aims to compare how these formulations are absorbed in the body when given separately or combined. Participants receive two different treatments in a crossover design vicadrostat and empagliflozin administered together then combined, or combined first then administered together. Each participant receives both treatments in separate periods, allowing comparison within the same individual. The study is conducted by Boehringer Ingelheim and includes random assignment to treatment sequences. During the study, participants undergo medical assessments including physical exams, vital signs, ECGs, and laboratory tests. Researchers measure drug concentration in plasma over up to 4 days after dosing, focusing on the area under the concentration-time curve and maximum concentration. The study involves healthy volunteers who provide informed consent and are monitored for safety throughout the trial.

CONDITIONS

Brief Title

A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here